First-in-Human Proof-of-Concept Study: Intralesional Administration of BQ788, an Endothelin Receptor B Antagonist, to Melanoma Skin Metastases by Wouters, Jasper et al.
Clinical Trial Results
First-in-HumanProof-of-ConceptStudy: IntralesionalAdministrationof
BQ788, an Endothelin Receptor B Antagonist, to Melanoma
Skin Metastases
JASPER WOUTERS,a ROBERT E. HUNGER,b TERENCE GARROD,a BENOIT DUBUIS,c THOMAS HUNZIKER,b JOOST J. VAN DEN OORD,a
RONIT LAHAV-LE COUTREc
aTranslational Cell and Tissue Research, Department of Imaging and Pathology, University of Leuven (KU Leuven), Leuven, Belgium;
bDepartment of Dermatology, Inselspital, Bern, Switzerland; cMelCure SA, Eclosion SA, Plan les Ouates, Switzerland
Access the full results at: Wouters-15-139.theoncologist.com
AUTHOR SUMMARY
LESSONS LEARNED
x Local tolerance of intralesional treatment of melanoma skin metastases with BQ788 is excellent.
x Hints of efficacy are observed, consisting of both direct effects (decreased expression of endothelin receptor B [EDNRB] and of
survival factors, reduced proliferation) and indirect effects (enhanced immune cell infiltration and angiogenesis).
x Patients in future trials shouldbescreened forEDNRBexpression levelprior to treatmentbecauseonlypatientswithhighEDNRB-
expressing melanomas (four of five) responded to BQ788.
x Futurestudies shouldbeperformed forat least2weeksbecause reduced lesiongrowthwasobserved in theonlypatient thatwas
treated for longer than 1 week.
ABSTRACT
Background. This first-in-human proof-of-concept study aimed
to check whether safety and preclinical results obtained by
intratumoral administration of BQ788, an endothelin receptor
B (EDNRB) antagonist, can be repeated in human melanoma
patients.
Methods.Three patients received a single intralesional BQ788
application of 3 mg. After 3–7 days, the lesions were measured
and removed for analysis.The administered dose was increased
toacumulativedosageof8mginpatient4(432.0mg,days0–3;
lesion removed on day 4) and to 10mg in patient 5 (33 3.3mg,
days 0, 3, and 10; lesion removed after 14 days). Control
lesionswere simultaneously treatedwith phosphate-buffered
saline (PBS). All sampleswereprocessed andanalyzedwithout
knowledge of the clinical findings.
Results. No statistical evaluation was possible because of the
number of patients (n 5 5) and the variability in the mode of
administration.Noadverseeventswereobserved, regardless of
administered dose. All observations were in accordance with
resultsobtained inpreclinical studies.Accordingly,nodifference
in degree of tumor necrosiswas detected between BQ788- and
PBS-treated samples. In addition, both EDNRB and Ki67 showed
decreasedexpression in patients 2 and5and, to a lesserextent, in
patient 1. Similarly, decreased expression of EDNRB mRNA in
patients2and5andofBCL2A1and/orPARP3inpatients2,3,and5
was found. Importantly, semiquantitatively scored immunohisto-
chemistry for CD31 and CD3 revealed more blood vessels and
lymphocytes, respectively, in BQ788-treated tumors of patients 2
and 4. Also, in all patients, we observed inverse correlation in
expression levels between EDNRB and HIF1A. Finally, in patient 5
(the only patient treated for longer than 1 week), we observed
inhibition in lesion growth, as shown by size measurement.
Conclusion.The intralesional applications of BQ788 were well
tolerated and showed signs ofdirectly and indirectly reducing the
viability of melanoma cells.The Oncologist 2015;20:1121–1122
DISCUSSION
In our preclinical studies, daily intratumoral administration of
BQ788 for 9 days resulted in inhibition of tumor growth with
associated enhanced angiogenesis, which, in accordance with
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in vitro data, was preceded by decreases in levels of EDNRB,
BCL2A1, and PARP3 and enhanced HIF1A expression [1, 2]. In
the current first-in-human study, we tested safety and re-
producibility of preclinical results by administering BQ788
(doses shown to be safe in human cardiovascular studies [3,
4]) in lesions of patients with melanoma. Our study, which
compared increasingcumulativedoses (3–10mg)andvarious
short treatmentmodalities (3–14days), establishedexcellent
local tolerance of the drug and did not reveal any side effects.
Although safety was ensured, the duration of treatment
(administered to the first four patients) was too short
(3–7 days) to evaluate whether the growth of tumors was
inhibited, as in preclinical studies [1, 2]. In patient 5, however
(the only patient treated for longer than 1 week, as in the
preclinical study), we observed inhibition in lesion growth, as
shown by size measurement. Our study stopped at this point
because of lack of funding; however, the latter finding in-
dicates that future studies should be performed for at least
2 weeks. As in preclinical studies [1, 2], early direct effects of
BQ788 administration on cancer cells were detected, such as
decreased EDNRB, BCL2A1, and PARP3, and reduced pro-
liferation, as shown by Ki67 staining (immunohistochemistry
results for patient 2 are shown in Fig. 1A). Despite inhibition
of tumor growth, hematoxylin and eosin staining did not
show any difference in degree of tumor necrosis between
BQ788- and vehicle-treated samples in preclinical studies [2].
Again,wedid notobserve anydifference in degree of necrosis
in this study as well. Patients in future trials should be
screened for EDNRB expression level prior to treatment
because only patients with high EDNRB expression (four of
five) responded to BQ788. BQ788 can also kill cancer cells
indirectly by improving the extravasation of immune cells
from the blood vessel into the tumor [5]. In preclinical in vivo
analyses, this indirect effect was manifested by an increase
in HIF1A expression and angiogenesis [1, 5]. The same
observation was repeated in this study, as shown by the
inverse correlation between HIF1A and EDNRB expression
(Fig. 1B). Semiquantitatively scored immunohistochemical
stainings for CD31 and CD3 revealed a higher abundance of
blood vessels and lymphocytes, respectively, in BQ788-treated
tumors, indicative of an indirect effect of BQ788. If these
observed signs of enhanced immune cell infiltration and
angiogenesis hold up in larger clinical trials, future investi-
gation should assess the potentially beneficial effect of
BQ788 administration on the efficacy of anti-programmed
death-1 receptor immunotherapy. Finally, emerging evidence
shows that EDN1-dependent EDNRB signal transduction is
crucial for paracrine resistance to BRAF inhibitors in hetero-
geneous tumors [6, 7]; BQ788 can be tested in combination
with BRAF inhibitors.
Author disclosures and references available online.
Figure1. EffectsofBQ788onproteinandgeneexpression inhuman
melanoma. (A): Summary of semiquantitatively scored immunohis-
tochemical stainings for EDNRB, Ki67, CD31, and CD3 in PBS- and
BQ788-treated tumors of patient 2. (B): Pearson correlation analysis
of HIF1A and EDNRBmRNA expression on all frozen samples (n5 6
in total; Pearson r52.86; p5 .0284; dashed line, 95% confidence
interval of the best-fit line).
Abbreviations: EDNRB, endothelin receptor B; PBS, phosphate-
buffered saline.
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